ID   SBC-3/ADM
AC   CVCL_M841
DR   Wikidata; Q54952169
RX   PubMed=3012965;
RX   PubMed=3012966;
RX   PubMed=3032107;
RX   PubMed=8104372;
RX   PubMed=10628341;
CC   Population: Japanese.
CC   Doubling time: 22 hours (PubMed=3012965); 45.9 hours (PubMed=10628341).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1678 ! SBC-3
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 14
//
RX   PubMed=3012965; DOI=10.18926/AMO/31923;
RA   Miyamoto H.;
RT   "Establishment and characterization of an adriamycin-resistant subline
RT   of human small cell lung cancer cells.";
RL   Acta Med. Okayama 40:65-73(1986).
//
RX   PubMed=3012966; DOI=10.18926/AMO/31920;
RA   Miyamoto H.;
RT   "In vitro chemosensitivity and radiosensitivity of an
RT   adriamycin-resistant subline of human small cell lung cancer cells.";
RL   Acta Med. Okayama 40:75-81(1986).
//
RX   PubMed=3032107;
RA   Kimura I., Ohnoshi T., Hiraki S., Miyamoto H.;
RT   "Establishment of adriamycin-resistant human small-cell lung cancer
RT   cells in culture: analysis of the mechanism of resistance and
RT   cross-resistance.";
RL   Gan To Kagaku Ryoho 14:830-836(1987).
//
RX   PubMed=8104372; DOI=10.18926/AMO/31598;
RA   Kiura K., Ohnoshi T., Tabata M., Shibayama T., Kimura I.;
RT   "Establishment of an adriamycin-resistant subline of human small cell
RT   lung cancer showing multifactorial mechanisms of resistance.";
RL   Acta Med. Okayama 47:191-197(1993).
//
RX   PubMed=10628341;
RA   Ikubo S., Takigawa N., Ueoka H., Kiura K., Tabata M., Shibayama T.,
RA   Chikamori M., Aoe K., Matsushita A., Harada M.;
RT   "In vitro evaluation of antimicrotubule agents in human small-cell
RT   lung cancer cell lines.";
RL   Anticancer Res. 19:3985-3988(1999).
//